Zydus Lifesciences ESG Score Improves to 69.4, Mourns Senior Executive Loss
Zydus Lifesciences has received an enhanced ESG score of 69.4 for FY25 from SES ESG Research, improving from the previous year's 67.8, maintaining its Medium Risk category. The company also announced the passing of Mr. Samir Desai, President-BU Biologics, ensuring regulatory compliance through timely disclosures to stock exchanges.
*this image is generated using AI for illustrative purposes only.
Zydus Life Science , a prominent player in the pharmaceutical industry, has announced the passing of Mr. Samir Desai, President-BU Biologics and a key member of the company's senior management. The company informed the stock exchanges BSE and NSE about this development on August 26, 2025.
Senior Management Change
Mr. Samir Desai, who held the position of President-BU Biologics at Zydus Lifesciences, passed away on August 26, 2025. As a result, he ceases to be part of the company's senior management team. The company expressed profound grief in its communication to the stock exchanges.
In compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Zydus Lifesciences provided the necessary details regarding this change in senior management.
Enhanced ESG Rating Performance
Zydus Lifesciences has received an improved Environmental, Social, and Governance (ESG) score for the financial year 2024-2025. SES ESG Research Private Limited has assigned the company an ESG score of 69.4, representing an improvement from the previous year's score of 67.8.
| ESG Performance Metrics: | Details |
|---|---|
| Current ESG Score: | 69.4 |
| Previous Year Score: | 67.8 |
| Score Improvement: | 1.6 points |
| Risk Category: | Medium Risk (60-70 range) |
| Rating Agency: | SES ESG Research Private Limited |
According to the rating framework, a score ranging between 60-70 is categorized as Medium Risk. The company noted that this rating was unsolicited, indicating an independent assessment of its ESG practices.
Regulatory Compliance and Disclosure
Dhaval N. Soni, Company Secretary and Compliance Officer of Zydus Lifesciences, signed the communications to the stock exchanges. The ESG rating disclosure was made in compliance with Regulation 30 of the Listing Regulations, read with SEBI Circulars dated November 11, 2024, and December 31, 2024.
The company ensured timely disclosure of these significant events, maintaining transparency with its stakeholders and complying with regulatory requirements. While Zydus Lifesciences faces the challenge of losing a key member of its senior management team, the improved ESG score indicates the company's ongoing efforts to enhance its sustainability and governance practices.
Historical Stock Returns for Zydus Life Science
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.81% | -0.32% | +0.58% | +18.61% | +13.13% | 0.0% |
19
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
